N-methyl Glycine (Sarcosine) for the Treatment of Obsessive Compulsive Disorder (OCD)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Several lines of evidence implicate glutamatergic dysfunction in the pathophysiology of
obsessive compulsive disorder (OCD). Sarcosine, also known as N-methylglycine, is an
endogenous antagonist of glycine transporter-I (GlyT-I), which potentiates glycine's action
at the glycine site of N-methyl-D-aspartate (NMDA) receptors. In this 10-week open-label
trial, we examined the efficacy and safety of sarcosine treatment in OCD patients.